source
- Regeneron’s ‘aversion’ to M&A questioned as bumper Q2 builds war chestCalls for Regeneron to step up dealmaking have intensified as the company has established an $18 billion cash pile and suffered clinical trial setbacks.BioSpace · 52m ago↗ source
- UCB stock slides despite Bimzelx revenue beating forecastsUCB shares dropped Thursday on investor concern that the Belgian pharma could be overpromising on its full-year forecast, even as sales of its lead drug topped analysts' expectations. The company r…Endpoints · 57m ago↗ source
- Garijo's plan to revamp Sanofi: an R&D cleanup, more M&A and a China pushThree months into her role as CEO at Sanofi, Belén Garijo gave some insight on how she plans to boost the French company’s mid- to long-term growth in the face of a looming patent cliff ...